RO7435846, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, PEMETREXED, Budenofalk 3mg magensaftresistente Hartkapseln, CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT D

Quick answer

RO7435846, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, PEMETREXED, Budenofalk 3mg magensaftresistente Hartkapseln, CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT D for Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cell Lung Cancer is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).